Continues to Strengthen Its Pandemic Preparedness and Biodefense Vaccine Portfolio ATLANTA, GA - April 9, 2025 (NEWMEDIAWIRE) ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent 09.04.2025 / 15:07 CET/CEST The issuer is solely responsible ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed  Additional data evaluating GEO-CM04S1 as ...

Investment analysts at Roth Capital issued their FY2029 EPS estimates for shares of GeoVax Labs in a research note issued on ...

Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd ...

Q4 2024 Earnings Call Transcript March 27, 2025 GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.79. Operator: Good afternoon. And welcome everyone to the ...

Get Our Latest Report on GOVX GeoVax Labs Price Performance NASDAQ GOVX opened at $1.08 on Wednesday. The company has a market cap of $10.19 million, a P/E ratio of -0.19 and a beta of 3.06 ...

Institutional investors wishing to attend the conference and schedule meetings with GeoVax leadership should contact their Roth MKM representative. GeoVax Labs, Inc. is a clinical-stage ...

Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the ...